x
Filter:
Filters applied
- Genomics and Proteomics
- Review ArticleRemove Review Article filter
- cancerRemove cancer filter
Publication Date
Please choose a date range between 2020 and 2020.
Keyword
- aging1
- cell metabolism1
- cell proliferation1
- chromatin1
- CRISPR/Cas1
- drug target1
- gene expression1
- histone deacetylase (HDAC)1
- inhibitor1
- longevity1
- maternal embryonic leucine zipper kinase (MELK)1
- metabolic disorder1
- OTS1671
- RNA interference (RNAi)1
- serine/threonine protein kinase1
- SIRT61
- sirtuin1
- sirtuin activator1
- small molecule1
- target specificity1
Genomics and Proteomics
2 Results
- JBC ReviewsOpen Access
Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators
Journal of Biological ChemistryVol. 295Issue 32p11021–11041Published online: June 9, 2020- Mark A. Klein
- John M. Denu
Cited in Scopus: 25Sirtuin 6 (SIRT6) is a nuclear NAD+-dependent deacetylase of histone H3 that regulates genome stability and gene expression. However, nonhistone substrates and additional catalytic activities of SIRT6, including long-chain deacylation and mono-ADP-ribosylation of other proteins, have also been reported, but many of these noncanonical roles remain enigmatic. Genetic studies have revealed critical homeostatic cellular functions of SIRT6, underscoring the need to better understand which catalytic functions and molecular pathways are driving SIRT6-associated phenotypes. - JBC ReviewsOpen Access
Enigmatic MELK: The controversy surrounding its complex role in cancer
Journal of Biological ChemistryVol. 295Issue 24p8195–8203Published online: April 29, 2020- Ian M. McDonald
- Lee M. Graves
Cited in Scopus: 9The Ser/Thr protein kinase MELK (maternal embryonic leucine zipper kinase) has been considered an attractive therapeutic target for managing cancer since 2005. Studies using expression analysis have indicated that MELK expression is higher in numerous cancer cells and tissues than in their normal, nonneoplastic counterparts. Further, RNAi-mediated MELK depletion impairs proliferation of multiple cancers, including triple-negative breast cancer (TNBC), and these growth defects can be rescued with exogenous WT MELK, but not kinase-dead MELK complementation.